Literature DB >> 16084758

Obese subjects with heart failure have lower N-terminal pro-brain natriuretic peptide plasma levels irrespective of aetiology.

Miguel Rivera1, Raquel Cortés, Antonio Salvador, Vicente Bertomeu, Fernando García de Burgos, Rafael Payá, Manuel Portolés, Raquel Taléns-Visconti, Luis Martinez-Dolz, Ricardo Valero, Begoña Sevilla, Vicente Climent.   

Abstract

N-terminal pro-brain natriuretic peptide (NT-proBNP) may be useful in the diagnosis of heart failure and ventricular dysfunction. Obesity is an independent cardiovascular risk factor. The purpose of this study was to measure NT-proBNP plasma levels in obese and non-obese subjects with heart failure and to compare levels in subjects with ischaemic and dilated aetiology. In this study, obese subjects had 63% lower NT-proBNP plasma levels than non-obese subjects (p < 0.01). In multivariate analysis, BMI was inversely associated with NT-proBNP plasma levels (p < 0.05) and a 17% decrease in natriuretic peptide levels was attributed to obesity (p < 0.036). When we analyzed data according to the aetiology of heart failure, we found that both groups (ischaemic and dilated) had a 65% decrease in NT-proBNP plasma levels in obese subjects compared to non-obese subjects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16084758     DOI: 10.1016/j.ejheart.2005.04.003

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  10 in total

1.  Impact of the look AHEAD intervention on NT-pro brain natriuretic peptide in overweight and obese adults with diabetes.

Authors:  Alain G Bertoni; Lynne E Wagenknecht; Dalane W Kitzman; Santica M Marcovina; Julia T Rushing; Mark A Espeland
Journal:  Obesity (Silver Spring)       Date:  2011-09-29       Impact factor: 5.002

2.  Galectin-3 levels are associated with right ventricular functional and morphologic changes in pulmonary arterial hypertension.

Authors:  Brett E Fenster; Luis Lasalvia; Joyce D Schroeder; Jamey Smyser; Lori J Silveira; J Kern Buckner; Kevin K Brown
Journal:  Heart Vessels       Date:  2015-05-15       Impact factor: 2.037

3.  Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies.

Authors:  Abigail May Khan; Susan Cheng; Martin Magnusson; Martin G Larson; Christopher Newton-Cheh; Elizabeth L McCabe; Andrea D Coviello; Jose C Florez; Caroline S Fox; Daniel Levy; Sander J Robins; Pankaj Arora; Shalender Bhasin; Carolyn S P Lam; Ramachandran S Vasan; Olle Melander; Thomas J Wang
Journal:  J Clin Endocrinol Metab       Date:  2011-08-17       Impact factor: 5.958

Review 4.  Combining tissue Doppler echocardiography and B-type natriuretic peptide in the evaluation of left ventricular filling pressures: review of the literature and clinical recommendations.

Authors:  Hisham Dokainish
Journal:  Can J Cardiol       Date:  2007-10       Impact factor: 5.223

5.  The relationship between body mass index and N-terminal pro-B-type natriuretic peptide in community-acquired pneumonia.

Authors:  Jong Seok Lee; Seok Hoon Ko; Jungyoup Lee; Ki Young Jeong
Journal:  Eur J Clin Nutr       Date:  2020-12-14       Impact factor: 4.884

6.  Impact of body mass index on plasma N-terminal ProB-type natriuretic peptides in Chinese atrial fibrillation patients without heart failure.

Authors:  Li-hui Zheng; Ling-min Wu; Yan Yao; Wen-sheng Chen; Jing-ru Bao; Wen Huang; Rui Shi; Kui-jun Zhang; Shu Zhang
Journal:  PLoS One       Date:  2014-08-21       Impact factor: 3.240

7.  Relationship between N-terminal pro-brain natriuretic peptide, obesity and the risk of heart failure in middle-aged German adults.

Authors:  Janine Wirth; Brian Buijsse; Romina di Giuseppe; Andreas Fritsche; Hans W Hense; Sabine Westphal; Berend Isermann; Heiner Boeing; Cornelia Weikert
Journal:  PLoS One       Date:  2014-11-25       Impact factor: 3.240

8.  N-terminal pro-B-type natriuretic Peptide in overweight and obese patients with and without diabetes: an analysis based on body mass index and left ventricular geometry.

Authors:  Seung Jei Park; Kyoung Im Cho; Sun Jae Jung; Sung Won Choi; Jae Won Choi; Dong Won Lee; Hyeon Gook Lee; Tae Ik Kim
Journal:  Korean Circ J       Date:  2009-12-30       Impact factor: 3.243

9.  Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment.

Authors:  Koichi Node; Teruo Inoue; Valentin Boyko; Ilan Goldberg; Enrique Z Fisman; Yehuda Adler; Ehud Schwammenthal; Zipora Matas; Solomon Behar; Alexander Tenenbaum
Journal:  Cardiovasc Diabetol       Date:  2009-01-28       Impact factor: 9.951

10.  RNA sequencing analysis and atrial natriuretic peptide production in patients with dilated and ischemic cardiomyopathy.

Authors:  Estefanía Tarazón; Esther Roselló-Lletí; Miguel Rivera; Ana Ortega; Maria Micaela Molina-Navarro; Juan Carlos Triviño; Francisca Lago; José Ramón González-Juanatey; Placido Orosa; José Anastasio Montero; Antonio Salvador; Manuel Portolés
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.